# US 2025/0361484 A1 · Use of memory lymphocyte population in liver cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0361484 A1
- Document ID: US20250361484A1
- Status: Published application
- Kind: A1
- Application number: 19/292,957
- Filed: 2025-08-07
- Published: 2025-11-27
- Earliest claimed: 2021-03-23
- Assignees: Cytocraft Biopharmaceutical Co., Ltd.
- Applicants: Cytocraft Biopharmaceutical Co., Ltd.
- Inventors: Ligong CHEN; Zhongjie SUN; Hong ZHAO; Jianqiang CAI; Junfan MA; Xiao GUO; Hailong QI; Qinglei XUE; Shuren ZHANG
- Web page: https://patentgrep.com/patent/US20250361484A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/53: Liver
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2307: Interleukin-7 (IL-7)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2506/11: from blood or immune system cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a method for treating liver cancer. The method includes administrating a therapeutic effective amount of a memory lymphocyte population to a subject in need thereof. The memory lymphocyte population contains at least one of the following marker molecules: leukocyte differentiation antigens CD3, CD4, CD8, CD16, CD56, CD62L and CD45RO.

## Claims

### Claim 1

A method for treating liver cancer, the method comprising:
administrating a therapeutic effective amount of a memory lymphocyte population to a subject in need thereof,
wherein the memory lymphocyte population comprises at least one of leukocyte differentiation antigens CD3, CD4, CD8, CD16, CD56, CD62L, or CD45RO.

### Claim 2 (depends on 1)

The method according to claim 1, wherein:
a main cell population in the memory lymphocyte population is central memory T cells;
a content of the main cell population is not less than 70%; and
a surface marker molecule of the main cell population is CD3+ CD45RA− CD45RO+CD62L+.

### Claim 3 (depends on 2)

The method according to claim 2, wherein a proportion of CD39+PD-1− cell subset in the central memory T cells with a surface marker molecule of CD4+ is 5% to 8%.

### Claim 4 (depends on 2)

The method according to claim 2, wherein a proportion of CD39+PD-1− cell subset in the central memory T cells with a surface marker molecule of CD8+ is 35% to 45%.

### Claim 5 (depends on 1)

The method according to claim 1, wherein when the memory lymphocyte population is in contact with DC cells loaded with tumor antigens, a proportion of cells with a surface marker molecule of CD62L+ in the memory lymphocyte population decreases, a proportion of cells with a surface marker molecule of CD62L−in the memory lymphocyte population increases, and an expression of IFN-γ increases.

### Claim 6 (depends on 1)

The method according to claim 1, further comprising, for the subject who has undergone radical hepatectomy:
subjecting the subject to transhepatic arterial infusion chemoembolization, TACE, therapy.

### Claim 7 (depends on 1)

The method according to claim 1, further comprising, prior to said administrating a therapeutic effective amount of a memory lymphocyte population to a subject in need thereof:
resuspending and culturing naive immune cells in a culture medium, to obtain the memory lymphocyte population,
wherein the culture medium comprises:
a basal culture medium;
interleukin-2;
interleukin-7;
interleukin-15;
an Anti-CD3 antibody; and
autologous plasma.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said culturing is performed at a temperature of 37° C. and 5 vol % of CO2 for 10 to 20 days.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the culture medium is supplemented every 2 to 4 days during said culturing until a cell density ranges from 5×105 cells/mL to 25×105 cells/mL, wherein the culture medium does not contain the autologous plasma in a third supplementation and each of subsequent supplementations.

### Claim 10 (depends on 7)

The method according to claim 7, wherein the naive immune cells are selected from peripheral blood mononuclear cells.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the peripheral blood mononuclear cells are resuspended in the culture medium at a density of 5×105 cells/mL to 20×105 cells/mL.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the peripheral blood mononuclear cells are obtained by:
mixing peripheral blood with heparin and centrifuging at 1,200 rpm/min to 2,000 rpm/min for 5 to 10 minutes to obtain an upper layer of autologous plasma and a lower layer of blood cells; and
diluting the blood cells with normal saline, loading the diluted blood cells on a surface of a lymphocyte separation solution, centrifuging the lymphocyte separation solution at 1,500 rpm/min to 2,000 rpm/min for 20 to 30 minutes, taking a mononuclear cell layer, mixing the mononuclear cell layer with the normal saline, centrifuging at 1,500 rpm/min to 2,000 rpm/min for 5 to 10 minutes, and washing the centrifuged mononuclear cell layer for 3 times, so as to obtain the peripheral blood mononuclear cells,
wherein a volume ratio of the blood cells, the normal saline and lymphocyte separation liquid is (1 to 3):(1 to 3):1.

### Claim 13 (depends on 7)

The method according to claim 7, further comprising, prior to said resuspending and culturing naive immune cells in a culture medium:
coating a culture container with a coating solution containing the Anti-CD3 antibody at 2° C. to 8° C. for 10 to 16 hours, wherein a volume of the coating solution is 2 to 8 ml/75cm2 of the culture container.

### Claim 14 (depends on 7)

The method according to claim 7, wherein in the culture medium:
a concentration of the interleukin-2 is 5×104 U/L to 1×106 U/L;
a concentration of the interleukin-7 is 1 ng/mL to 60 ng/mL;
a concentration of the interleukin-15 is 1 ng/mL to 60 ng/ml;
a concentration of the Anti-CD3 antibody is 0.5 μg/mL to 10 μg/mL; and
a concentration of the autologous plasma is 1 vol % to 10 vol %.

### Claim 15 (depends on 7)

The method according to claim 7, wherein in the culture medium:
a concentration of the interleukin-2 is 5×105 U/L;
a concentration of the interleukin-7 is 5 ng/ml;
a concentration of the interleukin-15 is 5 ng/ml;
a concentration of the Anti-CD3 antibody is 3 μg/mL; and
a concentration of the autologous plasma is 5 vol %.

### Claim 16 (depends on 7)

The method according to claim 7, wherein a pH value of the culture medium ranges from 7.2 to 7.4.

### Claim 17

A method for treating liver cancer in assistance with tumor resection operation, the method comprising:
administrating a therapeutic effective amount of a memory lymphocyte population to a who has undergone radical hepatectomy; and
subjecting the subject to TACE therapy,
wherein the memory lymphocyte population comprises at least one of leukocyte differentiation antigens CD3, CD4, CD8, CD16, CD56, CD62L, or CD45RO.

### Claim 18 (depends on 17)

The method according to claim 17, wherein a main cell population in the memory lymphocyte population is central memory T cells;
a content of the main cell population is not less than 70%; and
a surface marker molecule of the main cell population is CD3+CD45RA− CD45RO+CD62L+.

### Claim 19 (depends on 18)

The method according to claim 18, wherein a proportion of CD39+PD-1− cell subset in the central memory T cells with a surface marker molecule of CD4+ is 5% to 8%.

### Claim 20 (depends on 18)

The method according to claim 18, wherein a proportion of CD39+PD-1− cell subset in the central memory T cells with a surface marker molecule of CD8+ is 35% to 45%.
